Secondly, by comparing drugs with diverse characteristics and approval statuses, we aimed to offer a broader perspective on the safety issues of HDAC inhibitors in PTCL treatment. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.